Guido Reifenberger

Guido Reifenberger's AcademicInfluence.com Rankings

Guido Reifenberger

Philosophy

#4208

World Rank

#6640

Historical Rank

Logic

#1717

World Rank

#2546

Historical Rank

philosophy Degrees

Guido Reifenberger

Biology

#5440

World Rank

#7921

Historical Rank

Pathology

#63

World Rank

#136

Historical Rank

Neuroscience

#610

World Rank

#636

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Guido Reifenberger's Degrees

Doctorate Medicine University of Cologne
PhD Neuroscience University of Cologne

Why Is Guido Reifenberger Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Guido Reifenberger's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary (2016) (11090)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. (2021) (2388)
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma (2012) (2074)
International network of cancer genome projects (2010) (1839)
The WHO Classification of Tumors of the Nervous System (2002) (1770)
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. (2012) (1532)
DNA methylation-based classification of central nervous system tumours (2018) (1461)
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas (2009) (1062)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. (2012) (925)
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma (2011) (871)
Long-term survival with glioblastoma multiforme. (2007) (812)
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. (2009) (779)
Dissecting the genomic complexity underlying medulloblastoma (2012) (777)
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. (2017) (736)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas (2010) (714)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (2010) (667)
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma (2013) (637)
Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. (1993) (610)
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs (2016) (608)
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. (2014) (601)
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. (2014) (601)
Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. (1994) (599)
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. (2009) (561)
O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. (2005) (557)
International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading (2014) (514)
Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma (2014) (496)
cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” (2018) (492)
Histological classification and molecular genetics of meningiomas (2006) (488)
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2020) (486)
Glioblastoma: pathology, molecular mechanisms and markers (2015) (482)
CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. (1994) (481)
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics (2012) (472)
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. (2008) (456)
Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. (1998) (447)
Advances in the molecular genetics of gliomas — implications for classification and therapy (2017) (446)
A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. (2010) (419)
Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas (2005) (417)
MGMT testing—the challenges for biomarker-based glioma treatment (2014) (413)
Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. (1997) (389)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations (2012) (366)
Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing (2014) (362)
Identification and Functional Characterization of microRNAs Involved in the Malignant Progression of Gliomas (2010) (352)
BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1 (2013) (347)
Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. (1997) (322)
Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. (1994) (317)
Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. (2009) (303)
Oligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro‐Oncology (2003) (297)
Molecular targeted therapy of glioblastoma. (2019) (295)
cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading (2020) (293)
Temozolomide preferentially depletes cancer stem cells in glioblastoma. (2008) (290)
Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. (2003) (276)
Molecular diagnostics of gliomas: state of the art (2010) (271)
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers (2015) (269)
Comparison of 18F-FET PET and 5-ALA fluorescence in cerebral gliomas (2011) (269)
Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. (1999) (267)
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas (2011) (264)
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors (2005) (261)
Molecular pathogenesis of meningiomas (2004) (257)
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial (2015) (256)
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas (2020) (253)
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. (2007) (252)
Genetic Alterations and Aberrant Expression of Genes Related to the Phosphatidyl‐lnositol‐3′‐Kinase/Protein Kinase B (Akt) Signal Transduction Pathway in Glioblastomas (2003) (252)
Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups (2015) (245)
Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. (2001) (236)
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly (2012) (234)
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities (2015) (230)
Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays (2013) (230)
Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. (2005) (229)
Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling (2015) (225)
LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS (2019) (223)
Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker * (2008) (223)
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. (2013) (223)
Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. (1999) (212)
Pten signaling in gliomas. (2002) (210)
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET (2015) (204)
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation (2013) (204)
Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. (2005) (204)
Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. (1998) (203)
Glioma (2015) (202)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. (2003) (189)
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. (2012) (189)
Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. (1996) (186)
Prognostic Value of O-(2-18F-Fluoroethyl)-l-Tyrosine PET and MRI in Low-Grade Glioma (2007) (186)
Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients (2009) (185)
Analysis of p53 Mutation and Epidermal Growth Factor Receptor Amplification in Recurrent Gliomas with Malignant Progression (1996) (184)
Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. (2005) (183)
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. (2015) (183)
Molecular neuro-oncology in clinical practice: a new horizon. (2013) (182)
Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma (2014) (180)
Pathology and molecular genetics of astrocytic gliomas (2004) (177)
Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. (2013) (173)
Amplification and Expression of Cyclin D Genes (CCND1 CCND2 and CCND3) in Human Malignant Gliomas (1999) (171)
Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic? (2011) (171)
Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. (2009) (169)
Diagnostic Performance of 18F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of Glioma (2013) (168)
Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. (1999) (167)
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. (2007) (167)
Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. (1996) (166)
Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. (2015) (166)
The hallmarks of fibroblast ageing (2014) (166)
Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors (2001) (165)
Oligodendroglial Tumors: Refinement of Candidate Regions on Chromosome Arm 1p and Correlation of 1p/19q Status with Survival (2004) (163)
Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. (1999) (161)
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma (2016) (160)
Genomic and Expression Profiling of Glioblastoma Stem Cell–Like Spheroid Cultures Identifies Novel Tumor-Relevant Genes Associated with Survival (2009) (160)
Panel Review of Anaplastic Oligodendroglioma From European Organization for Research and Treatment of Cancer Trial 26951: Assessment of Consensus in Diagnosis, Influence of 1p/19q Loss, and Correlations With Outcome (2007) (156)
De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures (2010) (155)
Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations (2018) (154)
Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma (2018) (154)
Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas (2007) (153)
Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations (2013) (152)
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. (2006) (151)
Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell (2008) (150)
Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas (2004) (147)
Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity (2015) (145)
Recurrent chromosomal imbalances detected in biopsy material from oral premalignant and malignant lesions by combined tissue microdissection, universal DNA amplification, and comparative genomic hybridization. (1998) (141)
Microarray‐based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression (2005) (139)
Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. (2019) (138)
Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components (2006) (136)
cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation (2019) (136)
EANO guidelines for the diagnosis and treatment of ependymal tumors. (2018) (134)
Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma‐Tailored Gene Panel (2017) (130)
18F-FET PET differentiation of ring-enhancing brain lesions. (2006) (130)
RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival (2012) (129)
Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas (2010) (128)
The nuclear receptor tailless induces long-term neural stem cell expansion and brain tumor initiation. (2010) (127)
Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery (2012) (127)
Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas (2004) (126)
5-Aminolevulinic acid (5-ALA)-induced fluorescence in intracerebral metastases: a retrospective study (2012) (125)
Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. (2009) (125)
Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components (2002) (125)
Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells (2012) (121)
Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort (2014) (120)
Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC (2002) (118)
Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing (2010) (117)
Molecular characterization of long‐term survivors of glioblastoma using genome‐ and transcriptome‐wide profiling (2014) (117)
Molecular genetic alterations in glioblastomas with oligodendroglial component (2001) (117)
Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system (2009) (116)
The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells (2019) (114)
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors (2017) (114)
Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (2016) (109)
Role of O-(2-18F-Fluoroethyl)-l-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma (2013) (107)
Epidermal growth factor receptor expression in oligodendroglial tumors. (1996) (105)
Genetic alteration and expression of the phosphoinositol‐3‐kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas (2005) (103)
Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium (2018) (102)
Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. (2010) (101)
Chordoid Glioma of the Third Ventricle: Immunohistochemical and Molecular Genetic Characterization of a Novel Tumor Entity (1999) (101)
Oligodendroglial Tumors Frequently Demonstrate Hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) Tumor Suppressor Genes (2001) (98)
Expression of Bcl-2 family member Bid in normal and malignant tissues. (2002) (98)
Molecular genetic analysis of giant cell glioblastomas. (1997) (96)
Distinct Expression Pattern of Microtubule‐Associated Protein‐2 in Human Oligodendrogliomas and Glial Precursor Cells (2001) (96)
Comparative Pathology of Nerve Sheath Tumors in Mouse Models and Humans (2004) (96)
Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. (1999) (95)
Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy (2014) (95)
Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target (2003) (95)
Frequent loss of chromosome 9, homozygous CDKN2A/p14ARF/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas (2007) (94)
Centrosome amplification as a possible mechanism for numerical chromosome aberrations in cerebral primitive neuroectodermal tumors with TP53 mutations (1999) (93)
Low Frequency of SV40, JC and BK Polyomavirus Sequences in Human Medulloblastomas, Meningiomas and Ependymomas (2000) (91)
Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma (2008) (89)
Molecular signatures classify astrocytic gliomas by IDH1 mutation status (2011) (89)
Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. (2018) (87)
Molecular classification of gliomas. (2016) (87)
MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation. (2014) (86)
The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis (2012) (85)
MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape (2014) (85)
Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. (2013) (85)
MUTATION OF THE VON HIPPEL–LINDAU TUMOUR SUPPRESSOR GENE IN CAPILLARY HAEMANGIOBLASTOMAS OF THE CENTRAL NERVOUS SYSTEM (1996) (85)
Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery (2017) (85)
Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas (2000) (83)
MGMT promoter methylation in malignant gliomas (2010) (81)
Gliomatosis cerebri: Molecular pathology and clinical course (2002) (80)
SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation (2011) (79)
ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma (2009) (79)
Characteristic Chromosomal Imbalances in Primary Central Nervous System Lymphomas of the Diffuse Large B‐Cell Type (2000) (78)
Expression Profiling of t(12;22) Positive Clear Cell Sarcoma of Soft Tissue Cell Lines Reveals Characteristic Up-Regulation of Potential New Marker Genes Including ERBB3 (2004) (77)
Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. (2010) (77)
CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas (2020) (77)
Thalamic involvement in a spinocerebellar ataxia type 2 (SCA2) and a spinocerebellar ataxia type 3 (SCA3) patient, and its clinical relevance. (2003) (77)
Can the apparent diffusion coefficient be used as a noninvasive parameter to distinguish tumor tissue from peritumoral tissue in cerebral gliomas? (2004) (77)
Identification of novel oligodendroglioma‐associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray‐based expression profiling (2006) (76)
[The new WHO classification of tumors of the nervous system 2000. Pathology and genetics]. (2002) (76)
Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. (2014) (75)
Hypermethylation and Transcriptional Downregulation of the TIMP3 Gene is Associated with Allelic Loss on 22q12.3 and Malignancy in Meningiomas (2010) (75)
Imaging of Cu, Zn, Pb and U in human brain tumor resections by laser ablation inductively coupled plasma mass spectrometry (2006) (75)
Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status (2010) (73)
Loss of NOTCH2 Positively Predicts Survival in Subgroups of Human Glial Brain Tumors (2007) (68)
Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016 (2016) (68)
Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization (2006) (68)
Frequent In activation of CDKN2A and Rare Mutation of TP53 in PCNSL (1998) (67)
Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. (2010) (67)
Gliomatosis cerebri: no evidence for a separate brain tumor entity (2016) (67)
Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour‐associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood (2002) (66)
Multimodal target point assessment for stereotactic biopsy in children with diffuse bithalamic astrocytomas (2002) (65)
Aberrant expression of retinoic acid signaling molecules influences patient survival in astrocytic gliomas. (2011) (64)
Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas (2004) (63)
Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real‐time reverse transcription‐polymerase chain reaction (2006) (62)
Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction (2005) (62)
cIMPACT‐NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification (2017) (62)
Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. (2004) (62)
Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma (2007) (61)
Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site. (1995) (61)
Genetic and Expression Profiles of Cerebellar Liponeurocytomas (2004) (61)
Proteome-wide analysis reveals an age-associated cellular phenotype of in situ aged human fibroblasts (2014) (61)
NOA‐05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri (2011) (60)
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial (2018) (60)
MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM (2016) (60)
miR-23a-3p causes cellular senescence by targeting hyaluronan synthase 2: possible implication for skin aging. (2015) (59)
Expression of the CD34 antigen in pleomorphic xanthoastrocytomas (2003) (59)
miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells (2013) (58)
Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation (2000) (58)
Expression of Bcl-2 and amplification of c-myc are frequent in basaloid squamous cell carcinomas of the esophagus. (1999) (57)
Deletion mapping of the short arm of chromosome 1 identifies a common region of deletion distal to D1S496 in human meningiomas (1997) (56)
5-ALA-induced fluorescence behavior of reactive tissue changes following glioblastoma treatment with radiation and chemotherapy (2015) (56)
Genetic Alterations Commonly Found in Diffusely Infiltrating Cerebral Gliomas Are Rare or Absent in Pleomorphic Xanthoastrocytomas (2002) (56)
Glioma progression is shaped by genetic evolution and microenvironment interactions (2022) (56)
Association of Stem Cell-Related Markers and Survival in Astrocytic Gliomas (2011) (56)
Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR (2014) (56)
DNA hypermethylation and Aberrant Expression of the EMP3 Gene at 19q13.3 in Human Gliomas (2007) (55)
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. (2020) (55)
Molecular Neuropathology of Gliomas (2009) (55)
Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67 (2004) (54)
Anatomically based guidelines for systematic investigation of the central somatosensory system and their application to a spinocerebellar ataxia type 2 (SCA2) patient (2003) (54)
Allelic Gain and Amplification on the Long Arm of Chromosome 17 in Anaplastic Meningiomas (2002) (53)
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance (2016) (53)
cIMPACT‐NOW: a practical summary of diagnostic points from Round 1 updates (2019) (53)
Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated (2021) (51)
Cowden's disease: clinical and molecular genetic findings in a patient with a novel PTEN germline mutation (2003) (50)
Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q (2007) (50)
NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). (2010) (50)
Astrocytic tumors. (2009) (49)
Differential uptake of [18F]FET and [3H]l-methionine in focal cortical ischemia. (2006) (49)
Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation. (2009) (48)
Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion‐associated candidate genes (2012) (48)
The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression, and patient survival data in a therapeutic trial. (1995) (48)
Multiple intracranial juvenile xanthogranulomas. Case report. (2000) (48)
Frequent c-myc amplification in high-grade dysplasia and adenocarcinoma in Barrett esophagus. (2001) (48)
The Usefulness of Dynamic O-(2-18F-Fluoroethyl)-l-Tyrosine PET in the Clinical Evaluation of Brain Tumors in Children and Adolescents (2015) (48)
Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma (2017) (47)
Inhibition of Wnt/beta-catenin signaling downregulates expression of aldehyde dehydrogenase isoform 3A1 (ALDH3A1) to reduce resistance against temozolomide in glioblastoma in vitro (2018) (47)
Differential retinoic acid signaling in tumors of long- and short-term glioblastoma survivors. (2011) (46)
Coexpression of transforming growth factor-alpha and épidermal growth factor receptor in capillary hemangioblastomas of the central nervous system. (1995) (46)
Cerebroretinal vasculopathy mimicking a brain tumor: A case of a rare hereditary syndrome (1999) (45)
Transcriptional Profiling of the Nuclear Factor-&kgr;B Pathway Identifies a Subgroup of Primary Lymphoma of the Central Nervous System With Low BCL10 Expression (2007) (44)
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation (2018) (44)
Neurotransmitter Receptor Imbalances in Motor Cortex and Basal Ganglia in Hepatic Encephalopathy (2009) (44)
Expression of SoxE and SoxD genes in human gliomas (2007) (44)
FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma (2018) (43)
DNA methylation-based reclassification of olfactory neuroblastoma (2018) (43)
Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas (2011) (42)
Frequent biallelic inactivation and transcriptional silencing of the DIRAS3 gene at 1p31 in oligodendroglial tumors with 1p loss (2008) (42)
D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells (2018) (42)
DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment (2018) (42)
Molecular classification of human gliomas using matrix‐based comparative genomic hybridization (2005) (42)
Long-term survival of a patient with giant cell glioblastoma. Case report. (2001) (42)
Distribution of the carbohydrate epitope 3-fucosyl-N-acetyl-lactosamine (FAL) in the adult human brain. (1988) (41)
Expression of vimentin and glial fibrillary acidic protein in ethylnitrosourea-induced rat gliomas and glioma cell lines (2004) (41)
Sex differences in oncogenic mutational processes (2019) (41)
Unraveling the Glioma Epigenome—From Molecular Mechanisms to Novel Biomarkers and Therapeutic Targets (2011) (39)
Primary glioblastoma multiforme of the oculomotor nerve. Case report. (1996) (39)
Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro (2012) (38)
Pleomorphic xanthoastrocytoma with desmoplastic reaction: angiomatous variant. Report of two cases. (1990) (38)
Absence of immunoglobulin class switch in primary lymphomas of the central nervous system. (2005) (38)
USP8 Mutations in Pituitary Cushing Adenomas—Targeted Analysis by Next-Generation Sequencing (2018) (37)
Thymosin β 4 gene silencing decreases stemness and invasiveness in glioblastoma. (2014) (37)
Control of glioma cell migration and invasiveness by GDF-15 (2016) (37)
Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors (2007) (36)
Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells (2014) (36)
EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. (2018) (35)
Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup (2018) (35)
Chemical induction of brain tumors in rats by nitrosoureas: molecular biology and neuropathology. (1989) (34)
Lipoastrocytoma: a rare low-grade astrocytoma variant of pediatric age (2002) (34)
Comparison of O-(2-18F-Fluoroethyl)-l-Tyrosine and l-3H-Methionine Uptake in Cerebral Hematomas (2010) (33)
Analysis of human meningiomas for aberrations of the MADH2, MADH4, APM‐1 and DCC tumor suppressor genes on the long arm of chromosome 18 (2001) (33)
Sellar atypical teratoid/rhabdoid tumours in adults (2011) (32)
MiR‐16‐5p is frequently down‐regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy (2018) (32)
MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers (2013) (31)
Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA (2019) (31)
Inflammatory Demyelinating Brain Lesions Heralding Primary CNS Lymphoma (2012) (31)
Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype (2020) (31)
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities (2019) (30)
Element distribution is altered in a zone surrounding human glioblastoma multiforme. (2008) (30)
Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: Evidence for in situ T‐cell activation and therapeutic efficacy (2001) (30)
Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification. (2021) (30)
Absence of mutations in the putative tumor suppressor gene KLF6 in glioblastomas and meningiomas (2004) (30)
DNA methylation and allelic losses on chromosome arm 14q in oligodendroglial tumours (2006) (30)
Differential expression of glial- and neuronal-associated antigens in human tumors of the central and peripheral nervous system (2004) (29)
Diagnostic red flags: steroid‐treated malignant CNS lymphoma mimicking autoimmune inflammatory demyelination (2018) (28)
3-[123I]Iodo-α-methyl-L-tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis (2001) (28)
Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models. (2016) (28)
Epidermal growth factor receptor expression and growth fraction in human tumours of the nervous system (2004) (27)
Giant Cell Glioblastoma Is Associated With Altered Aurora B Expression and Concomitant p53 Mutation (2010) (27)
DNA Hypermethylation and Histone Modifications Downregulate the Candidate Tumor Suppressor Gene RRP22 on 22q12 in Human Gliomas (2012) (27)
Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma (2017) (26)
Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET (2018) (26)
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter-methylated malignant astrocytoma. (2020) (26)
Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q. (2010) (25)
Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy. (2001) (25)
Nos2 Inactivation Promotes the Development of Medulloblastoma in Ptch1+/− Mice by Deregulation of Gap43–Dependent Granule Cell Precursor Migration (2012) (25)
RANK (TNFRSF11A) is epigenetically inactivated and induces apoptosis in gliomas. (2012) (25)
Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults (2019) (25)
A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications. (2019) (24)
Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain (2020) (24)
MANGANESE deficiency. (2022) (24)
Primary diffuse leptomeningeal gliomatosis: unusual MRI with non-enhancing nodular lesions on the cerebellar surface and spinal leptomeningeal enhancement (2000) (23)
Supratentorial meningeal melanocytoma mimicking a convexity meningioma (2006) (23)
Potential Canonical Wnt Pathway Activation in High-Grade Astrocytomas (2012) (22)
Spatiotemporal expression gradients of the carbohydrate antigen CD15 (Lewis χ ) during development of the human basal ganglia (1999) (22)
Influencing the Wnt signaling pathway in multiple myeloma. (2011) (22)
Cross-species genomics reveals oncogenic dependencies in ZFTA/C11orf95 fusion-positive supratentorial ependymomas. (2021) (22)
Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors (2021) (22)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
Primitive Neuroectodermal Tumors of the Cerebral Hemispheres in Two Siblings with TP53 Germline Mutation (1998) (22)
Chemotherapy for intracranial ependymoma in adults (2016) (21)
Transcriptional control of O6‐methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma (2018) (21)
Tumours: introduction and neuroepithelial tumours (2008) (21)
The long noncoding RNA TP73‐AS1 promotes tumorigenicity of medulloblastoma cells (2019) (20)
CDKN 2 ( p 16 / MTS 1 ) Gene Deletion or CDK 4 Amplification Occurs in the Majority of Glioblastomast (2006) (20)
A 21‐YEAR‐OLD FEMALE WITH ATHIRD VENTRICULAR TUMOR (2006) (20)
Haplotype‐specific expression of the human PDGFRA gene correlates with the risk of glioblastomas (2008) (20)
Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics (2018) (20)
Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1 (2020) (20)
Glioblastoma with Adipocyte‐Like Tumor Cell Differentiation—Histological and Molecular Features of a Rare Differentiation Pattern (2009) (20)
Expression of CD15 in tumours of the nervous system (1992) (20)
Detection of Secondary Thalamic Degeneration After Cortical Infarction Using cis-4-18F-Fluoro- d-Proline (2007) (20)
Role of microRNAs Located on Chromosome Arm 10q in Malignant Gliomas (2016) (20)
Mixed gangliocytoma/pituitary adenoma. (2000) (20)
How Stemlike Are Sphere Cultures From Long-term Cancer Cell Lines? Lessons From Mouse Glioma Models (2014) (19)
Immunohistochemical determination of protein kinase C expression and proliferative activity in human brain tumors (2004) (19)
Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[18F]-fluoroethyl)-l-tyrosine PET (2020) (19)
Genotype and protein expression after bone marrow transplantation for adrenoleukodystrophy. (2007) (19)
Do host factors determine long-term survival in glioblastoma? A genome/transcriptome profiling study by the German Glioma Network. (2014) (19)
Distribution of anti-Leu-7, anti-Leu-11a and anti-Leu-M1 immunoreactivity in the brain of the adult rat (1987) (18)
Data Sets for the Reporting of Tumors of the Central Nervous System. (2019) (18)
Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD (2008) (17)
Molecular Genetic Analysis of Oligodendroglial Tumors Shows Preferential Allelic Deletions on 19 q and 1 p (2007) (17)
Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma (2019) (17)
Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild‐type glioblastoma (2014) (17)
Prognostic relevance of miRNA-155 methylation in anaplastic glioma (2016) (17)
Balo's concentric sclerosis followed by MRI and positron emission tomography (2004) (16)
Absence of detectable alterations in the putative tumor suppressor gene BTRC in cerebellar medulloblastomas and cutaneous basal cell carcinomas (2003) (15)
Corrigendum: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma (2012) (15)
Diagnostic difficulties in childhood bilateral thalamic astrocytomas. (2003) (15)
Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis (2013) (14)
Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells (2015) (14)
Fatal glioblastoma multiforme in a patient with neurofibromatosis type I: the dilemma of systematic medical follow-up (2007) (14)
The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma (2021) (14)
Pathology and Classification of Tumors of the Nervous System (2010) (13)
Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer. (2001) (13)
Nerve growth factor receptor in tumours of the human nervous system. Immunohistochemical analysis of receptor expression and tumour growth fraction. (1989) (13)
Primary anaplastic ganglioglioma with a small-cell glioblastoma component. (2008) (13)
Cerebral amyloidoma is characterized by B‐cell clonality and a stable clinical course (2018) (13)
Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis (2017) (12)
Chronophin is a glial tumor modifier involved in the regulation of glioblastoma growth and invasiveness (2016) (12)
New developments in the pathology of skull base tumors (2001) (12)
Rosetted glioneuronal tumor of the spine with overtly anaplastic histological features (2009) (12)
Genomic imbalances are rare in hairy cell leukemia (1999) (12)
A PRDX1‐p38α heterodimer amplifies MET‐driven invasion of IDH‐wildtype and IDH‐mutant gliomas (2018) (12)
Effects of recombinant human tumor necrosis factor on rodent gliomas and normal brain. (1991) (12)
Epidermal growth factor receptor expression in human malignant glioma: in vitro and in vivo effects of application of monoclonal antibodies to the epidermal growth factor receptor. (1994) (12)
Prostate adenocarcinoma metastasis in the pituitary gland. (2009) (11)
Neuropathology and Regional Imaging of Microcirculation, Tissue pH, Metabolites and Necroses in Cerebral RG2 and F98 Anaplastic Rat Glioma Transplantation Tumors (1987) (11)
Simultaneous extraction of nucleic acids and proteins from tissue specimens by ultracentrifugation: A protocol using the high‐salt protein fraction for quantitative proteome analysis (2009) (11)
Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial (2021) (11)
FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas (2019) (11)
Focal cortical dysplasia of the temporal lobe with late-onset partial epilepsy: serial quantitative MRI (2000) (10)
Combined therapy of medulloblastoma: review of 46 patients treated in a single institution. (1998) (10)
Integrative Genomic Analyses of Patient-Matched Intracranial and Extracranial Metastases Reveal a Novel Brain-Specific Landscape of Genetic Variants in Driver Genes of Malignant Melanoma (2021) (10)
Immunohistochemical demonstration of proliferating cell nuclear antigen in glioblastomas: pronounced heterogeneity and lack of prognostic significance (2005) (10)
Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma. (2010) (10)
Molecular Genetics of Oligodendroglial Tumors (1996) (9)
Molecular neuropathology of low-grade gliomas and its clinical impact. (2010) (9)
Leu-M1 immunoreactivity in the human brain (1987) (9)
Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banks (2015) (9)
Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches (2009) (9)
MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial. (2014) (9)
Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells (2021) (9)
GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types (2021) (8)
Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation (2019) (8)
Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective? (2020) (8)
Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival (2022) (8)
HIGH GRADE GLIOMAS (2012) (8)
Circular RNA profiling distinguishes medulloblastoma groups and shows aberrant RMST overexpression in WNT medulloblastoma (2021) (8)
Bevacizumab failure in glioblastomas. (2012) (7)
Targeted next‐generation sequencing of adult gliomas for retrospective prognostic evaluation and up‐front diagnostics (2020) (7)
Therapeutic Ribonucleic Acids in Brain Tumors (2009) (7)
Tumor-free survival of 7 years after gene therapy for recurrent glioblastoma (2003) (7)
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas (2022) (7)
Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors (2019) (7)
Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link? (2021) (7)
Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models (2020) (7)
Abstract 3687: An integrative genomics approach identifies distinct molecular and epigenetic subgroups of pediatric glioblastoma (2012) (7)
Impact of MGMT promoter methylation in glioblastoma of the elderly. (2011) (7)
Whole‐genome paired‐end analysis confirms remarkable genomic stability of atypical teratoid/rhabdoid tumors (2013) (6)
Evaluation of new 18F-labeled amino acids for brain PET (2005) (6)
The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors (2022) (6)
ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin) (2019) (6)
One week on/one week off regimen of temozolomide: Phase II trial in recurrent glioma (2007) (6)
EGFR gene amplification and variant III (EGFRvIII) mutation in primary and recurrent glioblastoma. (2016) (6)
Metastatic adenocarcinoma in cerebral astrocytoma: Clinicopathological and immunohistochemical study with review of the literature (2005) (6)
Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p (2018) (6)
Molecular diagnostics of brain tumors (2010) (6)
MRI characteristics and histological changes in glioblastoma after gene therapy. (1999) (6)
Thymosin beta 4 gene silencing decreases stemness and invasiveness in glioblastoma (2014) (6)
Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis (2020) (5)
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA‐09 trial (2020) (5)
PET in the Clinical Evaluation of Brain Tumors in Children and Adolescents (2015) (5)
Longitudinal stability of molecular alterations and drug response profiles in tumor spheroid cell lines enables reproducible analyses. (2021) (5)
EPIDERMAL GROWTH FACTOR RECEPTOR EXPRESSION IN GLIOBLASTOMAS: COMPARATIVE EVALUATION OF FOUR DIFFERENT ANTIBODIES (1993) (5)
136 Complete Resection of Contrast-Enhancing Tumor Volume is Associated With Improved Survival in Recurrent Glioblastoma Results From the DIRECTOR Trial (2015) (5)
In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line (1996) (5)
Droplet digital PCR-based analyses for robust, rapid, and sensitive molecular diagnostics of gliomas (2022) (4)
[Classification of gliomas. Current progress and perspectives]. (2015) (4)
Evidence-based management of adult patients with diffuse glioma - Authors' reply. (2017) (4)
RESULTS OF THE INTERNATIONAL INTERLABORATORY COMPARISON OF MGMT PROMOTER METHYLATION ANALYSIS INVOLVING TWENTY-THREE ACADEMIC CENTERS IN GERMANY, AUSTRIA AND THE NETHERLANDS (2014) (4)
Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion (2021) (4)
BI-32RISK FACTOR ANALYSIS FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WHO DID NOT RECEIVE SALVAGE THERAPY (2014) (4)
Pathology of tumours in laboratory animals. Tumours of the rat. Tumours of the peripheral nervous system. (1990) (4)
Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma. (2022) (4)
MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial. (2012) (3)
Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial. (2014) (3)
A common classification framework for histone sequence alterations in tumours: an expert consensus proposal (2021) (3)
Frequent Epigenetic Inactivation of DIRAS-1 and DIRAS-2 Contributes to Chemo-Resistance in Gliomas (2021) (3)
RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas (2019) (3)
Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide (2020) (3)
The landscape of genomic alterations across childhood cancers (2018) (3)
Eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) expression in glioblastoma is driven by ETS1- and MYBL2-dependent transcriptional activation (2022) (3)
[MRI of the cerebellopontine angle in patients with cleidocranial dysostosis]. (2001) (3)
IMMUNOTHERAPY/BIOLOGICAL THERAPIES (2013) (3)
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2022) (3)
Pathology and Classification of Tumors of the Central Nervous System (2019) (3)
The presence of TIM‐3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status (2020) (3)
Sarcomatous Meningioma: Diagnostic Pitfalls and the Utility of Molecular Testing. (2021) (3)
Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419). (2019) (3)
Clinical Epidermal Growth Factor Receptor Variant III ( EGFRvIII ) Positivity in EGFR-Ampli fi ed Glioblastomas : Prognostic Role and Comparison between Primary and Recurrent Tumors (2017) (2)
CELL BIOLOGY AND SIGNALING (2010) (2)
Correction: EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. (2019) (2)
IMMUNOHISTOCHEMISTRY IN BRAIN TUMOR CLASSIFICATION (1991) (2)
Immunochemistry of ethylnitrosourea-induced rat neurinomas, the RN6 neurinoma cell line and their transplantation tumors (2004) (2)
Glutaredoxin 2 promotes SP-1-dependent CSPG4 transcription and migration of wound healing NG2 glia and glioma cells: Enzymatic Taoism. (2021) (2)
RANK ( TNFRSF 11 A ) Is Epigenetically Inactivated and Induces Apoptosis in Gliomas 1 , 2 (2014) (2)
Clinical and molecular subgroups of ependymoma in adulthood: An analysis of the German Glioma Network. (2017) (2)
4EBP1/2 are active under standard cell culture conditions to regulate the translation of specific mRNAs (2020) (2)
MGMT promoter methylation status and DNA mismatch repair genes in paired primary and recurrent glioblastoma: A translational study of the German Glioma Network. (2010) (2)
MicroRNA: Biogenesis, Regulation, and Role in Primary Brain Tumors (2009) (2)
Interferon-b Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells (2014) (2)
EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastoma (2021) (2)
Sensitive detection of hydroxymethylcytosine levels in normal and neoplastic cells and tissues (2019) (2)
P01.013 Long-term analyses of the NOA-08 randomized phase III trial of temozolomide versus radiotherapy for elderly patients with malignant astrocytomas (2018) (2)
PROGNOSTIC AND PREDICTIVE BIOMARKER-BASED SUBGROUPS IN THE NOA-04 TRIAL (2014) (2)
Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status (2020) (2)
L1CAM as a Marker of an Aggressive Tumor Phenotype in Children with Juvenile Pilocytic Astrocytoma (2012) (2)
Does extent of resection matter in recurrent glioblastoma? Lessons from the DIRECTOR trial. (2015) (2)
Neuropathology and Molecular Genetics of Diffusely Infiltrating Cerebral Gliomas (2002) (2)
Application of Immunohistochemistry for Tumor Grading in Human Neuro-Oncology (1989) (2)
Quality assurance in neuropathology: Experiences from the round robin trials on IDH mutation and MGMT promoter methylation testing launched by the Quality Assurance Initiative Pathology (QuIP) in 2018 and 2019. (2020) (2)
Interferon-β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity (2020) (1)
Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis. (2022) (1)
Long-term survival in primary glioblastoma revisited: The contribution of isocitrate dehydrogenase mutations. (2013) (1)
ACTR-05. THE RANDOMIZED PHASE II ARTE TRIAL: BEVACIZUMAB PLUS HYPOFRACTIONATED RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2017) (1)
Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactions. (2022) (1)
PREDICTION OF PROGRESSION- FREE SURVIVAL IN PATIENTS WITH MALIGNANT GLIOMA USING DYNAMIC O-(2-18F-FLUOROETHYL)-L-TYROSINE PET (2016) (1)
The epigenetic evolution of gliomas is determined by their IDH1 mutation status and treatment regimen (2021) (1)
Anaplastic ganglioglioma—A diagnosis comprising several distinct tumour types (2022) (1)
P14.108 Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma (2019) (1)
Primary cilia contribute to the aggressiveness of atypical teratoid/rhabdoid tumors (2022) (1)
Intradural, extramedullary anaplastic astrocytoma arising from the first sacral nerve root. (2013) (1)
WNT/β-Catenin-Mediated Resistance to Glucose Deprivation in Glioblastoma Stem-like Cells (2022) (1)
The molecular evolution of glioblastoma treated by gross total resection alone. (2020) (1)
P02.04MICRORNA-MEDIATED DOWN-REGULATION OF NKG2D LIGAND EXPRESSION REDUCES GLIOMA CELL IMMUNOGENICITY. (2014) (1)
Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
HG-68COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA (2016) (1)
IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS (2020) (1)
Molecular classification of diffuse cerebral gliomas using genome- and transcriptome-wide profiling. (2015) (1)
MOLECULAR GENETIC ANALYSIS OF OLIGODENDROGLIAL TUMORS FOR ALLELIC DELETIONS ON 1p AND MUTATIONS OF THE CDKN2C GENE AT 1p32 (1999) (1)
ACTR-53. MGMT PROMOTER METHYLATION ANALYSIS FOR ALLOCATING COMBINED CCNU/TMZ CHEMOTHERAPY: LESSONS LEARNED FROM THE CeTeG/NOA-09 TRIAL (2019) (1)
Cancer Biology and Signal Transduction Interferon-b Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells (2014) (1)
SIG-03. HHIP-AS1 PROMOTES TUMOR SURVIVAL THROUGH STABILIZING DYNEIN COMPLEX 1 IN HEDGEHOG DRIVEN HUMAN BRAIN TUMORS (2019) (1)
RARE-19. CHEMOTHERAPY FOR SPINAL GLIOMAS IN ADULTS: A RETROSPECTIVE STUDY (2018) (1)
Progranulin (GRN), a protein mutated in frontotemporal dementia with ubiquitin-positive inclusions (FTLD-U), is abundantly expressed in human gliomas (2009) (1)
NI-19THE USE OF DYNAMIC O-(2-[18F]fluoroethyl)-L-TYROSINE-PET IN THE CLINICAL EVALUATION OF BRAIN TUMORS IN CHILDREN AND ADOLESCENTS. (2014) (1)
Symmetrical neurofibroma with Schwann cell predominance and focal formation of microneurinomas (2004) (1)
Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial ependymoma (2021) (1)
Rapid development of an atypical meningioma during Nivolumab therapy for metastatic renal cell carcinoma (2020) (1)
OMICS AND PROGNSTIC MARKERS (2013) (1)
Targeting the long non-coding RNA HHIP-AS1 in sonic hedgehog driven brain tumors (2016) (1)
Molecular Genetic, Host-Derived and Clinical Determinants of Long-Term Survival in Glioblastoma: First Results from the Brain Tumor Funders' Collaborative Consortium (2016) (1)
Therapy Resistance of Glioblastoma Stem Cells Induces Loss of Spherogenicity and Overcomes (2014) (1)
Erratum to: Gliomatosis cerebri: no evidence for a separate brain tumor entity (2016) (1)
First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas—a single-centre experience in 61 patients (2022) (1)
Histopathological Classification of Brain Tumors According to the Revised WHO Classification: Current State and Perspectives (1996) (1)
Clinical and molecular features associated with long-term survival of elderly patients with glioblastoma. (2017) (1)
New developments and controversies in the neuropathology of malignant gliomas. (1999) (1)
Diffuse leptomeningeal astrocytoma in a patient with infantile epilepsy. (2009) (1)
4EBP1/2 support tumorigenicity and cell survival during energetic stress by translationally regulating fatty acid synthesis (2022) (1)
Reply: Discriminating Ability of 18F-FET PET for Several Cerebral Neoplastic Lesions (2014) (1)
P11.45 Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models (2019) (0)
Effect of silencing thymosin beta 4 gene expression on stemness and invasiveness in glioblastoma. (2013) (0)
P14.29 Prediction of overall survival in patients with malignant glioma using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET (2019) (0)
First-line temozolomide therapy and MGMT status in elderly patients with primary CNS lymphoma (2009) (0)
GENE-33. INTEGRATED GLIOMA DIAGNOSTICS USING TARGETED NEXT-GENERATION SEQUENCING (2019) (0)
CSIG-04. WNT SIGNALING REGULATES ALDEHYDE DEHYDROGENASE 3A1 (ALDH3A1) TO INDUCE TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA CELLS (2017) (0)
Objective responses to chemotherapy in recurrent glioma: A prospective analysis from the German Glioma Network. (2011) (0)
Abstract PR02: Somatic CRISPR/Cas9-mediated tumor suppressor disruption enables versatile brain tumor modeling (2015) (0)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
Panel review of a set of anaplastic oligodendroglioma of EORTC trial 26951: interobserver variation, correlation with 1p/19q loss and clinical outcome (2007) (0)
Abstracts of the 52nd Workshop for Pediatric Research (2017) (0)
MBRS-48. IDENTIFICATION OF NOVEL THERAPEUTIC APPROACHES FOR MYC-DRIVEN MEDULLOBLASTOMA (2020) (0)
Oncometabolite D-2-hydroxyglutarate inhibits complement activation (2018) (0)
Mid-term treatment-related cognitive sequelae in glioma patients (2022) (0)
Identification of SGK1 as a novel predictive marker for treatment response in medulloblastoma. (2009) (0)
The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells (2019) (0)
Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup. (2019) (0)
EMBR-13. NOVEL SYNERGISTIC APPROACHES FOR TARGETED THERAPY OF MYC-DRIVEN MEDULLOBLASTOMA USING CRISPR/CAS9 GENE EDITING (2021) (0)
ACTR-16. PERIPHERAL BLOOD CD4+ MONONUCLEAR CELL FRACTIONS ARE ASSOCIATED WITH OVERALL SURVIVAL AT FIRST RECURRENCE OF IDH-WILDTYPE GLIOBLASTOMA AFTER STANDARD CHEMORADIOTHERAPY: SECONDARY ANALYSES OF THE PHASE II DIRECTOR TRIAL (2018) (0)
Longitudinal molecular trajectories of diffuse glioma in adults (2019) (0)
The epigenetic evolution of gliomas is determined by their 1 IDH 1 mutation status and treatment regimen 2 3 (2021) (0)
Proteome analysis of human glioma with 1p/19q LOH (2008) (0)
OC-0322: 4-miRNA signature and MGMT promoter methylation improve risk stratification in glioblastoma. (2020) (0)
Abstract 4349: The chromosome 17q oncogene LASP1 promotes metastatic dissemination of medulloblastoma (2010) (0)
Glioma Through the Looking GLASS: the Glioma Longitudinal Analysis consortium, molecular evolution of diffuse gliomas (2017) (0)
WHO classifi cation of central nervous system tumors 2016 : integration of histological features and molecular biomarkers for improved glioma diagnostics (2016) (0)
Abstract 5109: Somatic CRISPR/Cas9-mediated gene editing enables versatile brain tumor modeling (2018) (0)
Abstracts for the Tenth International Conference on Brain Tumour Research and Therapy (2005) (0)
Case Report Supratentorial meningeal melanocytoma mimicking a convexity meningioma (2006) (0)
Mild hyperphenylalaninemia (2020) (0)
AI-28RECURRENT GLIOBLASTOMAS AFTER TREATMENT WITH BEVACIZUMAB. (2014) (0)
ATRT-34. TARGETING PRIMARY CILIOGENESIS IN ATYPICAL TERATOID/RHABDOID TUMORS (2018) (0)
P45: Comprehensive genomic analysis of desmoplastic medulloblastomas reveals novel amplified genes and supports a monoclonal origin of the different histologic components (2005) (0)
56th Annual Meeting of the German Society for Neuropathology and Neuroanatomy, Tübingen, Germany, September 21 – 24, 2011 (2011) (0)
Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
Functional synapses between small cell lung cancer and glutamatergic neurons (2023) (0)
CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA (2018) (0)
Chemotherapy for intracranial ependymoma in adults (2016) (0)
Biomarkers for the diagnosis of brain tumor (2008) (0)
424 Aberrant retinoic acid signaling in astrocytic gliomas (2010) (0)
P02.07INTERFERON-β MODULATES THE INNATE IMMUNE RESPONSE AGAINST GLIOBLASTOMA INITIATING CELLS. (2014) (0)
Gene Expression Profiling of Gliomas – Improving the Understanding of Glioma Biology and Paving the Way for Molecular Classification (2008) (0)
Distribution of GOPC:ROS1 and other ROS1 fusions in glioma types (2021) (0)
LGG-10. PROTEOGENOMICS DISCRIMINATES PEDIATRIC AND ADULT PILOCYTIC ASTROCYTOMA AS DISTINCT BIOLOGICAL ENTITIES (2017) (0)
EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastoma (2022) (0)
Detection of Secondary Thalamic Degeneration After Cortical Infarction Using cis-4- 18 F-Fluoro- (2007) (0)
Anaplastic pilocytic astrocytoma-an IDH-wildtype diffuse glioma characterized by a distinct DNA methylation profile and combined alterations in MAPK pathway genes, CDKN2A/B and ATRX (2017) (0)
MEDU-20. HDAC AND NFκB ANTAGONISTS SYNERGISTICALLY INHIBIT GROWTH OF MYC-DRIVEN MEDULLOBLASTOMA (2018) (0)
OS07.5.A Report from the pooled analysis of the randomized trials NORDIC, NOA-8 and CE.6 on elderly patients with glioblastoma (2022) (0)
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities (2019) (0)
Metabolic Fatty Liver Disease (2009) (0)
P04.21MOLECULAR DIAGNOSTICS OF MALIGNANT GLIOMAS USING NEXT-GENERATION GENE PANEL SEQUENCING. (2014) (0)
[Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version]. (2019) (0)
BIOL-02. CELLULAR HETEROGENEITY CONTRIBUTES TO THE AGGRESSIVE BEHAVIOR OF MYC-DRIVEN MEDULLOBLASTOMA (2019) (0)
MPTH-23. LONG-TERM SURVIVAL WITH GLIOBLASTOMA IN THE ELDERLY (2016) (0)
Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery (2017) (0)
SGK1: a novel prognostic marker and potential drug target in medulloblastoma (2010) (0)
4-miRNA signature combined with MGMT methylation status in glioblastoma: A multicentric retrospective biomarker analysis with accompanying prospective cohort study. (2020) (0)
LGG-08. PROTEOGENOMICS REVEALS TWO DISTINCT BIOLOGICAL PILOCYTIC ASTROCYTOMA SUBGROUPS (2018) (0)
MBRS-16. HDAC AND NFκB ANTAGONISTS SYNERGISTICALLY INHIBIT GROWTH OF MYC-DRIVEN MEDULLOBLASTOMA (2018) (0)
Abstract 4594: Recurrent FGFR1 hotspot mutations represent a novel therapeutic target in childhood astrocytoma. (2013) (0)
Involvement Of Intracellular Calcium [ca2+]i In The Treatment Of Human Neuroblastoma With Cisplatin (cddp) And Topotecan (topo) (2014) (0)
Preoperative Embolization and Laser-Assisted Microsurgery of Intracranial Meningiomas (1989) (0)
EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection (2023) (0)
P04.27 Texture feature analysis to predict overall survival in recurrent glioblastoma treated in the DIRECTOR trial (2017) (0)
PATH-24. MOLECULAR SUBGROUPS OF ADULT EPENDYMAL TUMORS: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK (2017) (0)
Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
Cerebroretinal vasculopathy mimicking a brain tumor - Reply (2000) (0)
Correction to: DNA methylation-based reclassification of olfactory neuroblastoma (2018) (0)
ACTR-64. OBJECTIVE RESPONSES TO CHEMOTHERAPY IN RECURRENT GLIOMA DO NOT PREDICT BETTER SURVIVAL: A PROSPECTIVE ANALYSIS FROM THE GERMAN GLIOMA NETWORK (2018) (0)
PROLONGED SURVIVAL ASSOCIATED WITH THE USE OF INTRAOPERATIVE CARMUSTINE WAFERS ( GLIADEL w ) IN A PAEDIATRIC PATIENT WITH RECURRENT HIGH GRADE GLIOMA (2012) (0)
Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
DRES-13. EXTENDED TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK (2016) (0)
Low grade glioma (2006) (0)
LGG-38. PROTEOGENOMICS REVEALS THREE DISTINCT BIOLOGICAL PILOCYTIC ASTROCYTOMA SUBGROUPS (2018) (0)
CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
Promoter hypermethylation and aberrant expression of EMP3at 19q13.3 in oligodendrogliomas and astrocytomas (2007) (0)
EPEN-34. HIGH-THROUGHPUT DRUG SCREENING OF PRIMARY CULTURES REVEALS IRREVERSIBLE ERBB2 INHIBITION AS NOVEL THERAPEUTIC VULNERABILITY OF EPENDYMOMAS (2018) (0)
Can 18FDG-PET detect malignant transformation of neurofibromas in patients with neurofibromatosis type I? (2006) (0)
TRTH-28. HIGH THROUGHPUT SCREENING OF NOVEL HISTONE DEACETYLASE INHIBITORS FOR EPIGENETIC THERAPY OF PRIMARY BRAIN TUMORS (2017) (0)
ACTR-61. LONG-TERM ANALYSES OF THE NOA-08 RANDOMIZED PHASE III TRIAL (2018) (0)
Molecular diagnostics of malignant gliomas using next-generation sequencing (2015) (0)
BIOM-59. TERT PROMOTER MUTATION AND MGMT PROMOTER METHYLATION-MEDIATED SENSITIVITY TO TEMOZOLOMIDE IN IDH-WILDTYPE GLIOBLASTOMA: IS THERE A LINK? (2020) (0)
PCM-15SOMATIC CRISPR/Cas9-MEDIATED TUMOR SUPPRESSOR DISRUPTION ENABLES VERSATILE BRAIN TUMOR MODELING (2016) (0)
CMET-26. PERIOPERATIVE IMAGING OF BRAIN METASTASES: A EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY (EANO) YOUNGSTERS SURVEY (2018) (0)
EPEN-33. PHARMACOGENOMICS REVEALS SYNERGISTIC INHIBITION OF ERBB2 AND PI3K SIGNALING AS A THERAPEUTIC STRATEGY FOR EPENDYMOMA (2020) (0)
INHIBITING INVASION AND STEMNESS IN GLIOBLASTOMA BY THYMOSIN BETA 4 GENE SILENCING: A POTENTIAL THERAPEUTIC TARGET? (2014) (0)
OS2.2 Chemotherapy for spinal gliomas in adults (2019) (0)
Recurrent MET fusion genes represent a druggable target in paediatric glioblastoma 1 2 (2016) (0)
Molecular Neuropathology and 49th Annual Meeting of the German Society of Neuropathology and Neuroanatomy (2004) (0)
Buchbesprechungen·BookReviews (2009) (0)
Temozolomide selectively eliminates cancer stem cells in glioblastoma (2008) (0)
Mutational analysis of the SHH and PTCH genes in sporadic basal cell carcinomas (1998) (0)
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma (2022) (0)
Molecular genetic studies on gliomas and capillary hemangioblastomas of the central nervous system (1996) (0)
360O Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link? (2020) (0)
MAPK pathway activation in low-grade astrocytomas by BRAF gene duplications and activating mutations (2008) (0)
RANK (TNFRSF11A )I s Epigenetically Inactivated and Induces Apoptosis (2012) (0)
Update on quality assurance in neuropathology: Summary of the round robin trials on TERT promoter mutation, H3-3A mutation, 1p/19q codeletion, and KIAA1549::BRAF fusion testing in Germany in 2020 and 2021. (2023) (0)
Brain tumor imaging with [18F]fluoroethyl-L-tyrosine and PET (2006) (0)
Pathology of the Nervous System (1949) (0)
The Medulloblastoma Methylome Reveals New Epigenetic Regulatory Mechanisms (2013) (0)
High throughput screening of novel histone deacetylase inhibitors for epigenetic therapy of primary brain tumors (2016) (0)
EPEN-08. PHARMACOGENOMICS REVEALS ERBB2 AS A THERAPEUTIC TARGET IN PRIMARY EPENDYMOMA CULTURES (2019) (0)
Chemotherapy for adult patients with spinal cord gliomas. (2021) (0)
PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED (2021) (0)
Functional characterization of SGK1 in medulloblastoma biology (2009) (0)
OS2.1 Objective responses to chemotherapy in recurrent glioma do not predict better survival: A prospective analysis from the German Glioma Network (2018) (0)
Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival (2022) (0)
Microarray analysis of differential methylation during glioma progression (2004) (0)
SGK1 expression predicts treatment response in paediatric medulloblastoma (2009) (0)
Development and External Validation of a Clinical Prediction Model for Survival in Glioblastoma Patients (2020) (0)
DRES-05. MOLECULAR EVOLUTION OF DIFFUSE GLIOMAS AND THE GLIOMA LONGITUDINAL ANALYSIS CONSORTIUM (2018) (0)
ATRT-07. TARGETING PRIMARY CILIOGENESIS IN ATYPICAL TERATOID/RHABDOID TUMORS (2019) (0)
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation (2023) (0)
Histology and Molecular Genetics (2008) (0)
Abstract 203: Inhibiting invasion and stemness in glioblastoma by thymosin beta 4 gene silencing: a new therapeutic target (2014) (0)
CSIG-26. MOLECULAR DETERMINANTS OF SENSITIVITY TO PI3K/AKT/mTOR PATHWAY INHIBITION IN GLIOBLASTOMA (2018) (0)
Eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) expression in glioblastoma is driven by ETS1- and MYBL2-dependent transcriptional activation (2022) (0)
MOLECULAR GENETIC DETERMINANTS OF LONG-TERM SURVIVAL WITH GLIOBLASTOMA (2014) (0)
Abstract B88: TGF-β pathway-mediated escape from VEGF blockade is linked with angiogenesis and immune-suppression in murine glioma models (2017) (0)
Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma. (2018) (0)
P08.36 TGF-β pathway-mediated escape from VEGF blockade is linked with angiogenesis and immune-suppression in murine glioma models. (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Guido Reifenberger?

Guido Reifenberger is affiliated with the following schools:

Heinrich Heine University Düsseldorf
University of Tübingen
Technical University of Munich
University of Bonn
University of Zurich

Guido Reifenberger's Academic­Influence.com Rankings

Guido Reifenberger's Degrees

Why Is Guido Reifenberger Influential?

Guido Reifenberger's Published Works

Published Works

What Schools Are Affiliated With Guido Reifenberger?

Guido Reifenberger's AcademicInfluence.com Rankings